Anti-Human CD20 mAb, Seafrom (CAT#: STEM-CT-0004-ZJF)

The Anti-Human CD20 mAb manufactured by Seafrom is suitable for targeting B cells and modulating immune responses in cell therapy.
CD20 is a specific marker molecule on the surface of B lymphocytes, expressed on over 95% of normal or malignant B lymphocytes but not on hematopoietic stem cells, progenitor cells, or other normal tissues. It consists of 297 amino acids with a molecular weight of 33 kDa, and in its non-glycosylated form, it ranges from 34 to 36 kDa. The antigenic epitope of CD20 is a loop region composed of 43 amino acids located between the third and fourth transmembrane domains. After binding to antibodies, CD20 does not undergo significant internalization or cell surface shedding, making it an ideal target for treating B cell-related diseases. Since the original normal B cells are not affected by anti-CD20 monoclonal antibodies, these antibodies can effectively target lymphoma cells and normal B cells that express CD20, and even after most or all CD20-expressing lymphoma cells and normal B cells have been eliminated, the B cell population can still be reconstituted. As a result, anti-CD20 monoclonal antibodies are increasingly used in the treatment of B cell-related diseases.
Storage: Store at 2~8°C with a shelf life of 24 months. If needed for aliquoting, aliquots can be stored at -20°C for 6 months or at -80°C for 12 months, avoiding repeated freeze-thaw cycles.

Expression Host: CHO cells
Purity: >90%, analyzed by SDS-PAGE and high-performance liquid chromatography (HPLC)
Endotoxin Level: <0.1 EU/µg
Activity: Activity demonstrated through binding to PBMC cells
Purification Method: Protein A affinity chromatography
Appearance: Colorless transparent liquid

High purity, activity, and stability
High batch to batch consistency
Gmp production management standards

Anti-Human CD16 mAb, Seafrom
Anti-Human CD19 mAb, Seafrom
Anti-Human CD28 mAb, Seafrom
Anti-Human CD52 mAb, Seafrom